3B Blackbio DX Ltd
3B Blackbio DX Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #33 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
3B Blackbio DX Ltd Q4 FY26 key numbers
- Revenue
- The overall consolidated topline for FY27 is expected to be INR175-180 crores.
As stated in 3B Blackbio DX Ltd's Q4 FY26 earnings call transcript · published 14 Jun 2026. Reported figures, not investment advice.
The short version
The company targets a revenue growth of 15% to 20% for FY27 and onward. 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
From 3B Blackbio DX Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a revenue growth of 15% to 20% for FY27 and onward.
- Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28.
- The overall consolidated topline for FY27 is expected to be INR175-180 crores.
- The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%.
- Competition from China affects a small product segment.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
- Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores.
- Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments.
- There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities.
- M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates.
- The company aims to keep a cash reserve of INR 50 crores specifically for M&A deals.
2 more points from 3B Blackbio DX Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Coris contract initially was Euro 6 million for four years starting 2024.
- Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million).
- Around Euro 2.4 million remains to be executed through FY28.
- The Coris HAT order is expected to remain broadly similar in the current year.
- Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays.
- For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive.
2 more points from 3B Blackbio DX Ltd's call on order book
Create a free account to keep reading this call
What the Q4 FY26 call signalled
1 of 3 strong
3B Blackbio DX Ltd — Quarterly revenue & net profit
Q4 FY26 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q4 FY26 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic Ltd (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging and Path Lab Ltd (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q4 FY26 results?
The company targets a revenue growth of 15% to 20% for FY27 and onward. 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a below-average growth signal. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.